

Rybrevent[®] (amivantamab-vmjw) – New indication

- On September 19, 2024, [J&J announced](#) the [FDA approval](#) of [Rybrevent \(amivantamab-vmjw\)](#), in combination with carboplatin and pemetrexed, for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitution mutations, whose disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitor (TKI).
- Rybrevent is also approved for:
 - In combination with lazertinib for first-line treatment of NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations
 - In combination with carboplatin and pemetrexed for first-line treatment of NSCLC with EGFR exon 20 insertion mutations
 - As a single agent for previously treated NSCLC with EGFR exon 20 insertion mutations.
- The approval of Rybrevent for the new indication was based on MARIPOSA-2, a randomized, open-label study in patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations and progressive disease on or after receiving [Tagrisso[®] \(osimertinib\)](#). Patients were randomized to Rybrevent in combination with carboplatin and pemetrexed, carboplatin and pemetrexed, or Rybrevent as part of another combination regimen. The major outcome measure was progression-free survival (PFS). Overall survival (OS) and overall response rate (ORR) were key secondary outcome measures.
 - Median PFS was 6.3 months in the Rybrevent + carboplatin + pemetrexed arm vs. 4.2 months in the carboplatin + pemetrexed arm (hazard ratio 0.48, 95% CI: 0.36, 0.64; $p < 0.0001$).
 - The ORR was 53% in the Rybrevent + carboplatin + pemetrexed arm vs. 29% in the carboplatin + pemetrexed arm ($p < 0.0001$).
 - At the prespecified second interim analysis of OS, with 85% of the deaths needed for the final analysis, there was no statistically significant difference in OS.
- The recommended dose of Rybrevent, when used in combination with carboplatin and pemetrexed, is based on body weight.

Body weight at baseline	Recommended dose	Dosing schedule
< 80 kg	1400 mg	Weekly (total of 4 doses) from weeks 1 to 4 <ul style="list-style-type: none"> Week 1 - split infusion on day 1 and day 2 Weeks 2 to 4 - infusion on day 1 Weeks 5 and 6 - no dose
	1750 mg	Every 3 weeks starting at week 7 onwards
≥ 80 kg	1750 mg	Weekly (total of 4 doses) from weeks 1 to 4 <ul style="list-style-type: none"> Week 1 - split infusion on day 1 and day 2 Weeks 2 to 4 - infusion on day 1 Weeks 5 and 6 - no dose
	2100 mg	Every 3 weeks starting at week 7 onwards

- Refer to the Rybrevent drug label for dosing for its other indications.